Employers Hold the Line on GLP-1 Weight Loss Drug Coverage
New survey data shows employer coverage of GLP-1 obesity drugs has barely budged, with many companies seeking workarounds to limit costs.
Employer coverage of GLP-1 drugs for weight loss has flatlined, even as demand for medications like Ozempic and Wegovy surges across the country. A new survey reveals that roughly 36% of employers now cover GLP-1 medications for both diabetes and obesity treatment — an figure unchanged from 2025 and only marginally higher than the 34% recorded in 2024.
The stagnation signals that companies are pumping the brakes rather than expanding benefits, despite mounting pressure from employees and the broader healthcare community to make these high-cost treatments more accessible. Instead of broadening coverage, many employers are reportedly engineering alternative strategies to manage — or sidestep — the significant financial burden that widespread GLP-1 coverage would impose on their health plans.
Read more Meta Breaks Ground on First Major Canadian Data Center →
The drugs, which include popular brand-name treatments in the semaglutide class, carry steep list prices that can run into hundreds or thousands of dollars per month per patient, making large-scale coverage a daunting proposition for employers already grappling with rising healthcare costs. The near-zero growth in employer adoption over the past year suggests that affordability concerns continue to outweigh the potential long-term health savings that proponents argue these medications could deliver.
Analysts watching the employer benefits space note that the gap between employee demand and employer willingness to pay remains one of the defining tensions in workplace health coverage heading into open enrollment season. How companies navigate that tension — through tiered coverage, prior authorization requirements, or wellness program tie-ins — could shape access for millions of working Americans in the near term.
Continue reading at US Top News and Analysis
